Joseph J Larosa is EVP General Counsel and Secret of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 30,075 shares of REGN, which is worth approximately $21.5 Million. The most recent transaction as insider was on Dec 16, 2024, when has been sold 702 shares (Common Stock) at a price of $730.81 per share, resulting in proceeds of $513,028. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 30.1K
20.72% 3M change
0.13% 12M change
Total Value Held $21.5 Million

JOSEPH J LAROSA Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 16 2024
SELL
Payment of exercise price or tax liability
$513,028 $730.81 p/Share
702 Reduced 2.28%
30,075 Common Stock
Dec 09 2024
SELL
Payment of exercise price or tax liability
$387,204 $787.0 p/Share
492 Reduced 1.57%
30,777 Common Stock
Dec 06 2024
BUY
Grant, award, or other acquisition
-
2,332 Added 6.94%
31,269 Common Stock
Jul 11 2024
SELL
Open market or private sale
$2,031,980 $1088.95 p/Share
1,866 Reduced 4.69%
37,937 Common Stock
Jun 24 2024
SELL
Payment of exercise price or tax liability
$11,750,480 $1060.13 p/Share
11,084 Reduced 21.78%
39,803 Common Stock
Jun 24 2024
BUY
Exercise of conversion of derivative security
$8,029,431 $555.67 p/Share
14,450 Added 22.12%
50,887 Common Stock
May 21 2024
SELL
Open market or private sale
$1,855,488 $994.9 p/Share
1,865 Reduced 5.1%
34,678 Common Stock
Feb 26 2024
SELL
Open market or private sale
$990,000 $990.0 p/Share
1,000 Reduced 2.66%
36,543 Common Stock
Feb 22 2024
SELL
Open market or private sale
$967,650 $967.65 p/Share
1,000 Reduced 2.59%
37,543 Common Stock
Feb 07 2024
SELL
Open market or private sale
$950,000 $950.0 p/Share
1,000 Reduced 2.53%
38,543 Common Stock
Jan 03 2024
SELL
Payment of exercise price or tax liability
$22,344,963 $912.3 p/Share
24,493 Reduced 38.25%
39,543 Common Stock
Jan 03 2024
BUY
Exercise of conversion of derivative security
$13,588,440 $399.66 p/Share
34,000 Added 34.68%
64,036 Common Stock
Dec 11 2023
SELL
Payment of exercise price or tax liability
$564,696 $844.09 p/Share
669 Reduced 2.18%
30,036 Common Stock
Dec 08 2023
SELL
Payment of exercise price or tax liability
$718,909 $843.79 p/Share
852 Reduced 2.9%
28,572 Common Stock
Dec 08 2023
BUY
Grant, award, or other acquisition
-
2,133 Added 6.5%
30,705 Common Stock
Mar 23 2023
SELL
Payment of exercise price or tax liability
$5,404,319 $801.59 p/Share
6,742 Reduced 19.71%
27,471 Common Stock
Mar 23 2023
BUY
Exercise of conversion of derivative security
$2,704,300 $270.43 p/Share
10,000 Added 22.62%
34,213 Common Stock
Dec 16 2022
BUY
Grant, award, or other acquisition
-
2,752 Added 10.64%
23,110 Common Stock
Dec 09 2022
SELL
Payment of exercise price or tax liability
$370,613 $753.28 p/Share
492 Reduced 2.36%
20,358 Common Stock
Sep 09 2022
SELL
Payment of exercise price or tax liability
$15,152,801 $730.96 p/Share
20,730 Reduced 49.86%
20,850 Common Stock
Sep 09 2022
BUY
Exercise of conversion of derivative security
$8,112,900 $270.43 p/Share
30,000 Added 41.91%
41,580 Common Stock
Apr 07 2022
SELL
Open market or private sale
$3,687,705 $721.1 p/Share
5,114 Reduced 23.23%
16,900 Common Stock
Apr 01 2022
SELL
Open market or private sale
$3,542,212 $692.65 p/Share
5,114 Reduced 18.85%
22,014 Common Stock
Dec 11 2021
SELL
Payment of exercise price or tax liability
$463,045 $664.34 p/Share
697 Reduced 2.61%
26,051 Common Stock
Dec 09 2021
SELL
Payment of exercise price or tax liability
$12,992,379 $657.11 p/Share
19,772 Reduced 42.5%
26,748 Common Stock
JJL

Joseph J Larosa

EVP General Counsel and Secret
Tarrytown, NY

Track Institutional and Insider Activities on REGN

Follow REGENERON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN